SORIN-GROUP
Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced that new data show that its proprietary Phospholipid Reduction Treatment (PRT™) technology for use with tissue heart valves significantly reduces calcium absorption to help enhance valve durability.
Phospholipids in the pericardial tissue play a key role in the calcification process of tissue heart valves, as their phosphate heads act as binding sites for circulating calcium ions. PRT, which is used with Sorin’s Mitroflow PRT™ and Crown PRT™ valves, was designed to reduce the phospholipid content before the calcium binding can occur.
The results were presented by Prof. Paul Herijgers, M.D., University of Leuven, Belgium, at the 64th Congress of the European Society for Cardiovascular and Endovascular Surgery (ESCVS) in Istanbul1 . In the 60-day study, Prof. Herijgers and his team subcutaneously implanted pericardial tissue patches excised from commercially-available bioprostheses into laboratory rats. The researchers compared Sorin’s proprietary PRT coating to Linx AC™, which is used with the Trifecta™ valve (St. Jude Medical, USA), and ThermaFix™, which is used with the Perimount Magna™ valve (Edwards Lifesciences, USA) against a control group of standard glutaraldehyde-treated patches. The results showed that PRT technology significantly reduces calcium absorption compared to the control group.
“In previous works2,3 , our group reported that patient-prosthesis mismatch is associated with an increased incidence of structural valve degeneration in patients receiving tissue heart valves but also that anti-calcification treatment is effective in reducing that incidence significantly,” commented Prof. Herijgers. “This animal model study further strengthens our confidence that anti-calcification technologies are crucial to enhance valve durability and it also reinforces the message that surgeons play a key role in mitigating the risk of valve degeneration by minimizing patient-prosthesis mismatch and using tissue-treated technologies.”
“These results further validate the performance of our two PRT pericardial tissue heart valves currently available on the market, Mitroflow PRT and Crown PRT”, said Michel Darnaud, President, Cardiac Surgery Business Unit. “We are committed to providing the highest quality technology for cardiac surgical patients through continuous product innovation. Our patented PRT technology mitigates the potential for tissue heart valve calcification to further enhance the proven outstanding durability of previous-generation valves untreated with the phospholipid reduction technology.”
1. Herijgers et al. Anticalcification Treatments of Bioprosthetic Pericardial Heart Valve Tissue: a Comparative Experimental Study . 64th European Society for Cardiovascular and Endovascular Surgery. March 26-29, Istanbul. http://www.abstractagent.com/av2/afpr.asp?pdir=2015uccvs-program&plng=tur&au=1192&afu=157344
2. Flameng et al. Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves . J Thorac Cardiovasc Surg. 2014 Apr;147(4):1219-24. http://www.ncbi.nlm.nih.gov/pubmed/23623617
3. Flameng et al. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation. 2010 May 18;121(19):2123-9. http://www.ncbi.nlm.nih.gov/pubmed/20439787
About Sorin Group
Sorin Group (www.sorin.com
)
is a global, medical device company and a leader in the treatment of
cardiovascular diseases. The Company develops, manufactures, and markets
medical technologies for cardiac surgery and for the treatment of
cardiac rhythm disorders. With 3,900 employees worldwide,Sorin Group
focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary
products for open heart surgery and heart valve repair or replacement
prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators
and non invasive monitoring to diagnose arrhythmias and deliver
anti-arrhythmia therapies as well as cardiac resynchronization devices
for heart failure treatment) Every year, over one million patients are
treated with Sorin Group devices in more than 100 countries.
For more information, please visit www.sorin.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005714/en/
Contact:
Gabriele Mazzoletti
Director, Corporate Communications
Sorin
Group
Tel: +39 02 69969785
Mobile: +39 348 9792201
e-mail:
corporate.communications@sorin.com
or
Francesca
Rambaudi
Director, Investor Relations
Sorin Group
Tel:
+39 02 69969716
e-mail: investor.relations@sorin.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
REI Super Selects SS&C For Superannuation Administration1.5.2025 05:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 03:25:00 CEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
Andersen Global udvider sin europæiske værdiansættelseskapacitet gennem samarbejde med Value & Risk Valuation Services1.5.2025 03:03:00 CEST | Pressemeddelelse
Andersen Global fortsætter med at styrke sin værdiansættelseskapacitet gennem en samarbejdsaftale med Value & Risk Valuation Services, et fremtrædende europæisk værdiansættelsesfirma med hovedsæde i Tyskland og kontorer i Luxembourg og Østrig. Value & Risk Valuation Services blev grundlagt i 1996 og er et ledelsesejet firma, der har specialiseret sig i værdiansættelse af finansielle aktiver på tværs af forskellige aktivklasser og med varierende kompleksitet. Firmaet leverer også supplerende tjenester, herunder uafhængig prisverifikation (IPV), risikoanalyse og analyse af transaktionsomkostninger. Siden 2009 har virksomheden været ledet af Gil Bender, som er dedikeret til at levere kundecentrerede værdiansættelsesløsninger af høj kvalitet. Som en af de få europæiske udbydere, der tilbyder eksterne værdiansættelsestjenester i overensstemmelse med det europæiske direktiv om forvaltere af alternative investeringsfonde (AIFMD), opretholder Value & Risk de højeste industristandarder for over
From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 20251.5.2025 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in computing innovation, will return to COMPUTEX 2025 from May 20 to 23 under the theme "Omnipresence of Computing: AI Forward." Demonstrating how GIGABYTE’s complete spectrum of solutions spanning the AI lifecycle, from data center training to edge deployment and end-user applications reshapes the infrastructure to meet the next-gen AI demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428101781/en/ From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 2025 As generative AI continues to evolve, so do the demands for handling massive token volumes, real-time data streaming, and high-throughput compute environments. GIGABYTE’s end-to-end portfolio - ranging from rack-scale infrastructure to servers, cooling systems, embedded platforms, and personal computing—forms the foundation to accelerate AI breakthroughs across industr
Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies1.5.2025 00:00:00 CEST | Press release
Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world. “Over the past decade, Carl has forged impactful partnerships at the forefront of scientific innovation and delivered breakthrough products and superior formulations across categories, benefits and occasions, while fueling corporate innovation and advanced technologies,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “As we look to the future and delivering our bold Beauty Reimagined vision, we will transform our approach to innovation across the company—which includes e
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum